INDOCO REMEDIES LTD. - 532612 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Othes INDOCO REMEDIES LTD. - 532612 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mahika Panandikar & Others INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that German Health Authority (Berlin) had inspected Company's Oral Solid Dosage (OSD) manufacturing facility (Plant III) located at Baddi ('Facility'), from May 22, 2023 to May 25, 2023. The Facility has received EU GMP certification from German Health Authority (Berlin) confirming that Facility complies with the Good Manufacturing Practice requirements as referred in the EC Directive. Please find enclosed herewith press release in this regard. Indoco acquires 85% stake in US-based FFP Holding
The investment marks a significant milestonefor the company and will strengthen its position as a key player in the US market, Indoco said. INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of the Directors of the Company at their meeting held on June 5, 2023, approved the acquisition of 85% equity stake in FPP Holding Company, LLC ('FPP Holding'), a company registered in Delaware, USA ('Acquisition'). Consequently, Indoco Remedies Limited ('Company') has executed Equity Purchase Agreement on June 5, 2023 for the Acquisition. Please find enclosed a press release in this regard and details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFO/CMD/4/2015 dated September 9, 2015 in Annexure 'A' and 'B'. INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of the Directors of the Company at their meeting held on June 5, 2023, approved the acquisition of 85% equity stake in FPP Holding Company, LLC ('FPP Holding'), a company registered in Delaware, USA ('Acquisition'). Consequently, Indoco Remedies Limited ('Company') has executed Equity Purchase Agreement on June 5, 2023 for the Acquisition. Please find enclosed a press release in this regard and details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFO/CMD/4/2015 dated September 9, 2015 in Annexure 'A' and 'B'. INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Acquisition
In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of the Directors of the Company at their meeting held on June 5, 2023, approved the acquisition of 85% equity stake in FPP Holding Company, LLC ('FPP Holding'), a company registered in Delaware, USA ('Acquisition'). Consequently, Indoco Remedies Limited ('Company') has executed Equity Purchase Agreement on June 5, 2023 for the Acquisition. Please find enclosed a press release in this regard and details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFO/CMD/4/2015 dated September 9, 2015 in Annexure 'A' and 'B'.
Indoco Remedies slumps 5% as US FDA slaps OAI status to Goa plant
The US FDA has issued four observations under Form 483 following the inspection of Indoco's Goa facility back in February. INDOCO REMEDIES LTD. - 532612 - Indoco Remedies Limited Clinical Research Organisation (CRO), Anacipher, Receives Clearance On Remote Record Assessment From USFDA
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Company's Clinical Research Organisation, AnaCipher, located in Hyderabad, was inspected by the United States Food and Drug Administration (USFDA) in July 2022. The USFDA has confirmed that no objectionable conditions were observed during their remote assessment. You are requested to kindly take the same on record INDOCO REMEDIES LTD. - 532612 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Indoco Remedies Limited Goa Plant II- Classified With OAI Status
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that United States Food and Drug Administration (USFDA) had inspected Company's Sterile Facility (Plant II) located at Goa('Facility'), from February 20, 2023 to February 28, 2023. The said Facility had 4 observations in Form 483. USFDA has determined the inspection classification of this Facility as OAI (Official Action Indicated). The Company is committed towards working with USFDA for remediation of the concerns on highest priority.